Table 2.
Comparison of progression between patients with solitary and multiple PTC
| Multiple PTC | solitary PTC | P value | |
|---|---|---|---|
| Number |
136 |
376 |
|
| Male/female |
32/104 |
95/281 |
0.451 |
| Mean age (yr) ± SD |
44.3 ± 15.1 |
42.5 ± 17.4 |
0.226 |
| Mean size (cm) ± SD |
1.29 ± 1.44 |
1.67 ± 1.15 |
0.048 |
| Micro variant |
84 (61.8%) |
147(39.1%) |
< 0.001 |
| Tall cell variant |
17 (12.5%) |
38 (10.1%) |
0.267 |
| Extrathyroidal invasion |
35 (25.9%) |
93 (24.7%) |
0.450 |
| Vascular invasion |
15 (11.0%) |
16 (4.3%) |
0.006 |
| Hashimoto’s thyroiditis |
36 (26.5%) |
61 (16.2%) |
0.007 |
| Lymph node metastasis |
74 (54.4%) |
123 (32.7%) |
< 0.001 |
| Distant metastasis |
6 (4.4%) |
14 (3.7%) |
0.447 |
| Recurrence |
21 (15.4%) |
15 (4.0%) |
< 0.001 |
| 10-year survival rate |
125 (91.9%) |
341 (90.7%) |
0.579 |
| BRAFv600E mutation |
75 (55.1%) |
188 (50%) |
0.176 |
| Family history |
7 (5.1%) |
6 (1.6%) |
0.032 |
| TNM stage |
|
|
|
| I |
56 (41.2%) |
186 (49.5%) |
|
| II |
40 (29.4%) |
111 (29.5%) |
0.031 |
| III |
24 (17.6%) |
59 (15.7%) |
|
| IV | 16 (11.8%) | 20 (5.3%) |
The TNM stage is based on the AJCC Cancer Staging Manual, 7th edition (2002).